RevMab

anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), Rabbit Monoclonal (RM451)

CHF 459.00
In stock
REV-31-1343-00-R100100 µlCHF 459.00
More Information
Product Details
Synonyms Mitogen-activated Protein Kinase p44/42
Product Type Recombinant Antibody
Properties
Clone RM451
Isotype Rabbit IgG
Source/Host Rabbit
Immunogen/Antigen A phospho-peptide corresponding to human Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204).
Application

Immunohistochemistry (IHC): 1:100-1:200
Western Blot (WB): 1:1000-1:2000

Crossreactivity Human
Specificity

This antibody reacts to human p44/42 MAPK (Erk1/2) only when phosphorylated at Thr202 and Tyr204. There is no cross-reactivity to Erk1/2 that is not phosphorylated. This antibody may also react to mouse or rat Phospho- Erk1/2 (Thr203/Tyr205) as predicted by immunogen homology.

Purity Protein A purified.
Purity Detail Protein A affinity purified from an animal origin-free culture supernatant.
Concentration N/A
Formulation Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide.
Isotype Negative Control

Rabbit IgG

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Accession Number P28482
Declaration Manufactured by RevMab Biosciences.
Shipping and Handling
Shipping BLUE ICE
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Extracellular signal-regulated kinases 1 and 2 (also known as ERK1/2, p44/42, or MAPK3/1) belong to a family of conserved serine/threonine protein kinases known as mitogen-activated protein kinases (MAPKs) that are involved in many cellular programs such as proliferation, differentiation, motility and survival. The ERK1/2 signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors and cytokines. The primary activators of ERK1/2 are MEK1 and MEK2 which activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187 in ERK1 and ERK2, respectively. Several downstream targets of ERK1/2 have been identified, including p90RSK and the transcription factor Elk-1. ERK1/2 are negatively regulated by MAPK phosphatases as well as by chemical inhibitors of MEK. The ERK pathway is disrupted in many types of cancer and thus is an important target for diagnosis and treatment.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.